The opening of the Academician Expert Forum of Medical Homotherapy Drugs and Application Technology

Forum site

Volkswagen · Poster Journalist Sun Yi Photography Tang Miao Yantai Report

On the afternoon of August 18th, the Academician and Expert Forum of Medical Homotherapy Drugs and Application Technology opened at Yantai Bay International Convention and Exhibition Center in Yantai. Manager Luo Zhigang presided over the event. This forum focuses on the cutting -edge fields such as medical isotopic drugs and application technology, and builds a communication platform to gather excellent development forces.

Yantai Dongcheng Pharmaceutical Group Co., Ltd. Chairman Yiyi

Luo Zhigang, general manager of Yantai Dongcheng Pharmaceutical Group Co., Ltd.

Build a platform to gather industrial development joint efforts

As a sub -forum of "2022 International Conference on Pharmaceutical Innovation and Development", this event Yantai Taitung Cheng Pharmaceutical Group Co., Ltd., Yantai Muping District People's Government and Yantai Biomedical Health Industry Development Co., Ltd.

As the organizer of this event, Yiyi Yingyi, chairman of Yantai Dongcheng Pharmaceutical Group Co., Ltd., said that with the introduction of the "2021-2035 Medical Homerly Development Plan" and "Yantai Medical Pymophastin Industry Development Plan", The "International Medical Homotherapy Innovation Application Base" is a carrier, gathered to integrate the integrated nuclear medical industry, and the world's "nuclear" eyes will focus on Yantai. Taking this forum as an opportunity, Tongcheng and other nuclear pharmaceutical companies will share the innovative situation of global nuclear medicine and seek a new article on the development of Chinese nuclear medicine.

Luo Zhigang, general manager of Yantai Dongcheng Pharmaceutical Group Co., Ltd., expressed warm welcome and sincere greetings to the guests from afar.

Luo Zhigang said that Shi Feng's nuclear medical industry has risen, the top -level design at the national level, the release of Yantai's medical isotope industry planning, and the discussion and research of medical isotope drugs and application technology is of great significance. This meeting provided you with an opportunity to learn and communicate with experts. It was also a good opportunity for Dongcheng Pharmaceutical to make suggestions to promote the rapid development of nuclear medical care through the suggestions of experts.

Deng Jianjun, an academician of the Chinese Academy of Engineering and chief engineer of the Institute of Fluid Physics, Institute of Physics of the Chinese Academy of Engineering

Experts on Dao Dao sharing nuclear medicine diagnosis and treatment trends

Focusing on the development of nuclear medicine, this forum invited many experts and scholars to "talk" on the spot. For example, Deng Jianjun, an academician of the Chinese Academy of Engineering, Deng Jianjun, chief engineer of the Institute of Fluid Physics of the Institute of Physics of the Chinese Academy of Engineering, Jiang Jiandong, a member of the Chinese Academy of Engineering, a member of the Chinese Academy of Medical Sciences, and a professor of the dean of Beijing Union Medical Medicine, and Lei Pingsheng Pan Gang, deputy director of the Strategic Consultation Center of the Chinese Academy of Engineering, Huang Gang, president and professor of Shanghai Health Medical College, Yang Zhi, director, professor, and doctoral supervisor of Peking University Cancer Hospital. Professor, doctoral, doctoral supervisor, and member of the Party Committee of the School of Pharmacy, Peking University, Li Zhongjun, a member of the Academy, and other experts and scholars.

The forum set up a seminar. Relevant experts and scholars combined with the development of Yantai nuclear medical treatment, we conducted in -depth discussions on the cutting -edge information and diagnosis and application trends of nuclear medicine, and were committed to clarifying the innovation direction and prospect of nuclear medicine.

Deng Jianjun, an academician of the Chinese Academy of Engineering and chief engineer of the Institute of Fluid Physics, Institute of Physics of the Chinese Academy of Engineering, believes that in recent years, the state has attached great importance to the development of nuclear medical care. Yantai has vigorously promoted the development of nuclear medical care with a forward -looking strategic vision and development, and has gone at the forefront of the country and the industry. At the same time, Yantai should also pay attention to complementing shortcomings, innovate from many aspects, and have more independent intellectual property rights.

Lei Pingsheng, a researcher and doctoral tutor of the Chinese Academy of Medical Sciences, believes that in terms of nuclear medical care, relying on the strong support of provincial and cities, Yantai will have great development prospects and space. Enterprises should go all out and down -to -earth, and continue to make up shortcomings to promote development. As one of the leading domestic nuclear medical companies, Dongcheng Pharmaceutical should play a leading role and contribute to the development of nuclear medical undertakings.

Subsequently, relevant experts shared around the results and development trends of their respective research fields.

Huang Gang, the principal and professor of Shanghai Health Medical College, shall make relevant reports on the title of "Nuclear Medicine Molecular Imaging and targeted drug evaluation"; Zhang Yunhuang, the main technical person in charge of the main technical person in the production of medical homogencin production, Report to the Minsheng-Nuclear Medical Application of Reactor "; Tian Guoxin, a researcher at the Chinese Institute of Atomic Energy Sciences, made a report entitled" Treatment of radioactive nuclear separation technology and prospects "; Hu Kuan, a researcher and doctoral instructor of the Institute of Pharmaceutical Research of the Union Medical College, shared the "Several Frontier and Development Trends of targeted nuclear drugs".

For this forum, Huang Gang said: "Thanks for the forum to provide us with a platform for communication. This also requires us to actively learn from the valuable experience of professional organizations such as the Asian Oceania Nuclear Medicine and Biology (AOFNMB) to solve radioactive drug management There are many issues such as use and the cultivation of professional and technical talents. "

At present, radioactive drugs for targeted therapy have received widespread attention. "A targeted nuclear medicine focuses on the integrated diagnosis and treatment nuclear medicine, bringing new hope for the middle and late tumors in the middle and late stages of refractory metastasis." Hu Kuan said that China has gradually become a major nuclear drug country, but there is still a certain gap between the power of nuclear medicine. It should be surrounded by the stuck neck technology, so that my country will have a group of FIC nuclear drugs with independent intellectual property rights. At the same time The source innovation. Gathering forces to brighten the new business card of "Nuclear Medical" city

In recent years, Yantai ’s biomedical industry has developed rapidly, and it has taken the lead in the field of medical isotopes. The industrial foundation is very solid. At present, Yantai has Dongcheng Pharmaceuticals, one of the leading companies in the field of medical isotope drugs in my country, and has formed a wealth of domestic mainstream medical isotopes of pharmaceutical products.

This forum also focuses on the new ideas and new paths in cutting -edge fields such as medical isotopic drugs and application technology. It will point out the direction of the long -term development of the field and polish the new "nuclear medical" city business card for Yantai.

As a local pharmaceutical company in Yantai, Dongcheng Pharmaceutical has become a large -scale pharmaceutical company group covering the three major areas of chemical medicine, nuclear medicine, and large health. Its core products are sodium sodium and chondanicin sulfate, and more than 90%of the products are sold to more than 40 countries and regions in Europe, America, and Asia Pacific. In recent years, the company has entered a high -tech barrier and high -end nuclear medicine industry. It has successively acquired a number of domestic nuclear pharmaceutical companies, and has basically completed nuclear medicine from nuclear supply, R & D innovation, clinical transformation, production and distribution, and marketing services. The layout of the entire industry chain, the nuclear pharmaceutical ecosystem has begun to take shape.

"In the future, Dongcheng Pharmaceutical will continue to increase the investment in innovation R & D, continue to build a nuclear medical and health industry with independent intellectual property rights, and continuously improve the nuclear drug ecological chain. Welfare contribution. "Yu Shouyi, chairman of Dongcheng Pharmaceutical.

- END -